about
Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replicationPeroxynitrite decomposition catalyst prevents apoptotic cell death in a human astrocytoma cell line incubated with supernatants of HIV-infected macrophages.An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim ProjectActivities of masked 2',3'-dideoxynucleoside monophosphate derivatives against human immunodeficiency virus in resting macrophagesSynthesis and biological application of a new heterodinucleotide with both anti-HSV and anti-HIV activityHCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitorsRecent Transmission Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central ItalyHIV-1 Genetic Variability and Clinical ImplicationsInfluenza virus A (H5N1): a pandemic risk?HEFFICON: HIV Effectiveness Italian Conference.Phylogenesis and Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus Infection.A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus.Apoptosis and telomeres shortening related to HIV-1 induced oxidative stress in an astrocytoma cell lineCharacterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs.Ellagic acid and Annona muricata in the chemoprevention of HPV-related pre-neoplastic lesions of the cervixPrediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study).Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitorsPathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs.The contribution of peroxynitrite generation in HIV replication in human primary macrophages.Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria.Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants.The human polyomaviruses KI and WU: virological background and clinical implications.Macrophages: a crucial reservoir for human immunodeficiency virus in the body.Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients.Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replicationThe genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing.Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitorsMacrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir.Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.HIV-1 drug resistance in recently HIV-infected pregnant mother's naïve to antiretroviral therapy in Dodoma urban, Tanzania.Virologic correlates of adherence to antiretroviral medications and therapeutic failure.Administration of fludarabine-loaded autologous red blood cells in simian immunodeficiency virus-infected sooty mangabeys depletes pSTAT-1-expressing macrophages and delays the rebound of viremia after suspension of antiretroviral therapyEfficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.Interpretation systems for genotypic drug resistance of HIV-1.Clinical implications of HIV-1 drug resistance in the neurological compartment.Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.Antiviral profile of HIV inhibitors in macrophages: implications for therapy.
P50
Q24634299-7B30FA74-432C-4B17-B0D0-F68E86E7A87BQ24806585-83957CA0-1ADF-4B97-8E93-1D085D80A340Q26991980-EB4604C8-5779-4A23-8F4B-0406907ED8BFQ28343822-67E30E9D-D173-471E-90E5-025F7630E7F4Q28370175-2CB7D01B-4564-4030-A60A-476EB41BCF33Q28481038-91AC46DA-4748-4511-9816-A5952FEFE0F2Q28547222-C3898851-520F-4536-863F-B0DC643DD717Q30352010-E1B1D9B0-3DD3-4FCF-BD3F-80016691F1B7Q30362812-B76A51B4-FB26-49E0-B63A-CFBDA455CABAQ30375005-D16879F2-3F08-4F2C-9DCC-10920B384DF0Q30403636-1666D138-E4A4-46BA-8CB5-FE32C7B153AFQ31438248-12FFD055-B600-40F4-94E4-91DE5C16A1A4Q33450956-D40A8E37-B0B3-4E65-81AE-2A900A0D2DD3Q33483060-1CD1CD99-8DA0-41B2-A1E1-523C35374754Q33599424-51A08E37-97F8-41E9-A46E-29217CF95A6FQ33669321-D0DA3B93-4E52-460C-83FF-C9CEE096A3C5Q33703634-18A2D388-D5E5-4B59-9594-AD3EAD4E1B93Q33770040-96DD40A2-4857-4A46-8194-C331CA5C7D39Q33841435-7D316B81-7711-472E-AA29-5A7B6325E8F3Q33850686-81628B9F-B2E2-4FB8-9880-48A51898DD2BQ34007680-0C9B610F-F0C6-4D11-9FE9-A7F8BC6EFA25Q34083250-5CF23DAB-DC5D-49C9-816F-C47AB8D88589Q34108775-EB923B1B-3FD6-4614-AEAF-033630367A9BQ34284896-2C9CF687-0FB3-4F3A-982A-F00D53F85FF9Q34351951-F242CE7D-6E92-431E-BB79-7901638B2A55Q34427702-58525240-1B33-4191-98C5-C1983AFB5552Q34475126-B3B4D152-BD9F-4A09-9D3E-F2C25D75C558Q34477315-9B3FD4D4-B4DC-414D-948A-1C8D84D68FFBQ34558508-A4333226-D10B-40D0-9099-5818E87CECDAQ34717615-60140F05-EC48-4FF2-8C95-FCC1B5C3C339Q34726282-A2F67011-19B2-4340-AB86-D4A414A982A9Q34846620-72E4C5D5-D5B9-4C37-AFF6-3239C0553115Q34993070-31D74B60-6C25-4489-8E0C-FE6897718B5CQ35057785-3CDB2DC3-EA8F-43FF-AAC9-3A7F011A7F15Q35139258-958440E2-24E9-4787-9F4F-1AB2E09A6942Q35542299-5249E909-D6DE-4FE8-8F67-0775B937D340Q35682387-AB33E959-3068-412F-951D-5D22D0F48CDBQ35682394-699DA082-DED5-4416-B1F7-D99510C72534Q35694729-D7A78D62-B33F-4536-992C-AC08CA6B8805Q35768574-C6D80C98-FEEB-4531-9FF8-7894B4EE2680
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Carlo Federico Perno
@ast
Carlo Federico Perno
@en
Carlo Federico Perno
@es
Carlo Federico Perno
@nl
type
label
Carlo Federico Perno
@ast
Carlo Federico Perno
@en
Carlo Federico Perno
@es
Carlo Federico Perno
@nl
prefLabel
Carlo Federico Perno
@ast
Carlo Federico Perno
@en
Carlo Federico Perno
@es
Carlo Federico Perno
@nl
P106
P21
P31
P496
0000-0002-0825-5388